Alkermes Plc (ALKS) is a global biopharmaceutical company committed to developing innovative medicines to improve the lives of patients suffering from serious chronic conditions. Founded in 1987, the Dublin, Ireland-based company has operational headquarters in Waltham, Massachusetts. Alkermes specializes in developing treatments in the areas of mental health, addiction, schizophrenia, and oncology.
One of the company's core beliefs is that drug delivery technologies can significantly improve the effectiveness and safety of different types of drugs, enabling better patient outcomes. Alkermes has developed many proprietary, clinically meaningful advances in drug delivery technologies, which have led to the development of therapies with improved attributes and outcomes.
The company's rich pipeline of drug candidates includes both commercial products and advanced clinical development programs. These products are designed to address unmet medical needs of patients in major therapeutic areas including schizophrenia, depression, opioid dependence, alcohol dependence, and multiple sclerosis, among others.
Some of the company's notable products include ARISTADA® (for schizophrenia), VIVITROL® (for alcohol and opioid dependence), and LYBALVI™ (for schizophrenia and bipolar I disorder). Moreover, Alkermes has several collaborative arrangements with some of the world's leading pharmaceutical companies such as Amgen, Biogen, and Johnson & Johnson.
The company's business model combines proprietary technologies, sophisticated research and development capabilities, and expertise in manufacturing and commercialization. Alkermes' strategy is centered on maximizing the value of the portfolio through a combination of advancing the pipeline, optimizing the profitable products, and leveraging the capabilities to drive long-term growth.
Alkermes employs approximately 2,400 people worldwide and prides itself on a company culture that encourages innovation, collaboration, and the pursuit of scientific excellence. Their goal is to translate advances in science and technology into therapies that help patients regain valuable aspects of their lives that were lost due to illness. It is guided by its responsibility to patients, employees, and shareholders in everything it does.
In recent years, Alkermes is increasing its focus on research and development and investing in new technologies and treatments, in line with its commitment to making a lasting impact on global health. Despite facing challenges in the biopharmaceutical industry, the company has proven its resilience and continues to be a recognized leader in its field. In summary, Alkermes Plc is a company committed to transforming lives through science, driven by its passion for innovation and the need to make a substantial, positive impact on healthcare outcomes.